| [1] |
Mujais S,Story K. Peritoneal dialysis in the US: evaluation of outcomes in contemporary cohorts[J]. Kidney Int, 2006, 103(70): 21-26.
|
| [2] |
Mujais S,Nolph K,Gokal R, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis[J]. Perit Dial Int, 2000, 20(Suppl 4): S5-S21.
|
| [3] |
Flessner MF. The transport barrier in intraperitoneal therapy[J]. Am J Physiol Renal Physiol, 2005, 288(3): F433-F442.
|
| [4] |
Teitelbaum I. Ultrafiltration failure in peritoneal dialysis: a pathophysiologic approach[J]. Blood Purif, 2015, 39(1-3): 70-73.
|
| [5] |
严豪,方炜,李振元, 等. 可溶性酪氨酸激酶2融合蛋白对尿毒症腹膜透析大鼠腹膜形态和功能的影响[J]. 中华肾脏病杂志, 2010, 26(7): 525-529.
|
| [6] |
Goffin E,Combet S,Jamar F, et al. Expression of aquaporin-1 in a long-term peritoneal dialysis patient with impaired transcellular water transport[J]. Am J Kidney Dis, 1999, 33(2): 383-388.
|
| [7] |
Aroeira LS,Aguilera A,Sánchez-Tomero JA, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions[J]. J Am Soc Nephrol, 2007, 18(7): 2004-2013.
|
| [8] |
Kinashi H,Ito Y,Mizuno M, et al. TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis[J]. J Am Soc Nephrol, 2013, 24(10): 1627-1642.
|
| [9] |
De Alvaro F,Castro MJ,Dapena F, et al. Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure[J]. Adv Perit Dial, 1993, 9: 56.
|
| [10] |
Kolesnyk I,Noordzij M,Dekker FW, et al. A positive effect of AⅡ inhibitors on peritoneal membrane function in long-term PD patients[J]. Nephrol Dial Transplant, 2009, 24(1): 272-277.
|
| [11] |
La Milia V,Di Filippo S,Crepaldi M, et al. Mini-peritoneal equilibration test: a simple and fast method to assess free water and small solute transport across the peritoneal membrane[J]. Kidney Int, 2005, 68(2): 840-846.
|
| [12] |
Stoenoiu MS,Ni J,Verkaeren C, et al. Corticosteroids induce expression of aquaporin-1 and increase transcellular water transport in rat peritoneum[J]. J Am Soc Nephrol, 2003, 14(3): 555-565.
|
| [13] |
De Arteaga J,Ledesma F,Garay G, et al. High-dose steroid treatment increases free water transport in peritoneal dialysis patients[J]. Nephrol Dial Transplant, 2011, 26(12): 4142-4145.
|
| [14] |
Yool AJ,Morelle J,Cnops Y, et al. AqF026 is a pharmacologic agonist of the water channel aquaporin-1[J]. J Am Soc Nephrol, 2013, 24(7): 1045-1052.
|
| [15] |
Kawanishi H,Kawaguchi Y,Fukui H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study[J]. Am J Kidney Dis, 2004, 44(4): 729-737.
|
| [16] |
Vizzardi V,Sandrini M,Zecchini S, et al. Encapsulating peritoneal sclerosis in an Italian center: thirty year experience[J]. J Nephrol, 2016, 29(2): 259-267.
|
| [17] |
Hirahara I,Inoue M,Okuda K, et al. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis-a multicentre study in Japan[J]. Nephrol Dial Transpl, 2007, 22(2): 560-567.
|
| [18] |
Balasubramaniam G,Brown EA,Davenport A, et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis[J]. Nephrol Dial Transpl, 2009, 24(8): 3209-3215.
|
| [19] |
Korte MR,Fieren MW,Sampimon DE, et al. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study[J]. Nephrol Dial Transpl, 2011, 26(2): 691-697.
|
| [20] |
Hirahara I,Kusano E,Morishita Y, et al. Matrix metalloproteinase-2 as a superior biomarker for peritoneal deterioration in peritoneal dialysis[J]. World J Nephrol, 2016, 5(2): 204-212.
|
| [21] |
Dohi K. Surgical techniques for prevention of recurrence after total enterolysis in encapsulating peritoneal sclerosis[J]. Adv Perit Dial, 2008, 24: 51-55.
|
| [22] |
Baranowska-Daca E,Torneli J,Popovich RP, et al. Use of bethanechol chloride to increase available ultrafiltration in CAPD[J]. Adv Perit Dial, 1995, 11: 69-72.
|